NCT01151930 is a clinical trial of SCB01A in Malignant Solid Tumour, sponsored by SynCore Biotechnology Co., Ltd..

Who is sponsoring NCT01151930?

NCT01151930 is sponsored by SynCore Biotechnology Co., Ltd..

What drugs are being tested in NCT01151930?

Interventions in NCT01151930: SCB01A.

What condition does NCT01151930 study?

NCT01151930 studies Malignant Solid Tumour.

Is NCT01151930 still recruiting?

NCT01151930 is currently no longer available. Last updated 17 November 2020.

Last reviewed 2020-11-17 · How we verify

NCT01151930

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-Term Compassionate Use Study for Continued Administration of SCB01A-01

NO LONGER AVAILABLE Last updated 17 November 2020

What this trial tests

trial testing SCB01A in Malignant Solid Tumour. No longer available.

Quick facts

Lead sponsor	SynCore Biotechnology Co., Ltd.
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS

Drugs / interventions tested

SCB01A — full drug profile →

Conditions studied

Malignant Solid Tumour — all drugs for Malignant Solid Tumour →

Sponsor

SynCore Biotechnology Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Malignant Solid Tumour. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective is to characterize the safety profile of long-term exposure to SCB01A when administered to cancer subjects with advanced solid tumors. Furthermore, the efficacy profile will also be explored in this study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.
Shiah HS, Chiang NJ, Lin CC, Yen CJ, et al · · 2021 · cited 5× · PMID 33245172 · DOI 10.1002/onco.13612

Verify or expand the search:

Other trials of SCB01A

Trials testing the same drug.

NCT03020823 — To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer · Phase 2 · terminated

Other recruiting trials for Malignant Solid Tumour

Currently open trials in the same condition.

NCT07044336 — Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) · Phase 3 · recruiting

Other SynCore Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT03126435 — EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX · Phase 3 · completed
NCT03020823 — To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer · Phase 2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01151930 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SynCore Biotechnology Co., Ltd.
Last refreshed: 17 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01151930.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing